Sorrento Therapeutics launches $170m mAB JV for ‘undruggable’ targets
Oncology company Sorrento Therapeutics has formed an antibody JV in a deal worth over $170m with a Californian research centre.
Archives for September 28, 2015
“Money has returned to the market”: Envigo mulls biopharma role in preclinical recovery
Demand for biopharmaceutical testing is in part responsible for higher capacity utilisation but, despite encouraging signs, it is too early to say if preclinical pricing will improve accordingly says Envigo.
Polpharma hires ex Lupin, Teva and Merck KGaA man to lead biosimilar push
Polpharma has continued its biosimilar-focused hiring spree and appointed Maurice Chagnaud as its CEO.